Travere Therapeutics asumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Travere Therapeutics (TVTX) with a Buy rating and $30 price target The primary focus is the Filspari commercial launch in the U.S., which is now the only fully approved, non-immunosuppressing, kidney-targeted therapy positioned to potentially replace standard of care, the analyst tells investors in a research note. The firm says Filspari looks to leverage a key opportunity to move into earlier lines of therapy for IgAN.